Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder
BACKGROUND: Venlafaxine is a dual serotonin (5-HT) and norepinephrine reuptake inhibitor. The specific dose at which it begins to efficiently engage the norepinephrine transporter (NET) remained to be determined. Paroxetine is generally considered as a selective 5-HT reuptake inhibitor but exhibits...
Main Authors: | Aldosary, F. (Author), Blier, P. (Author), James, J.S (Author), Norris, S. (Author), Ritchie, J.C (Author), Tremblay, P. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
The pharmacological management of depression – Update 2017
by: Elzbieta Osuch, et al.
Published: (2017-03-01) -
Acute dystonia with concomitant use of amitriptyline and paroxetine
by: Sachin Ratan Gedam, et al.
Published: (2017-01-01) -
Venlafaxine poisoning-induced severe hypoglycemia in a non-diabetic patient: a case report
by: Thomas Schiestel
Published: (2020-09-01) -
Bradycardia Caused by interaction of Venlafaxine and Cyclosporine: A case report
by: Marzieh Azizi, et al.
Published: (2019-09-01) -
Antidepressant Use and the Risk of Major Adverse Cardiovascular Events in Patients Without Known Cardiovascular Disease: A Retrospective Cohort Study
by: Ha Young Jang, et al.
Published: (2020-12-01)